Article Archive
ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs
March 7, 2023
Read moreRead moreModerna and Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
February 22, 2023
Read moreRead moreElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 5, 2023
Read moreRead moreElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T's T Cell Therapy Programs Targeting Core Oncogenic Drivers
November 15, 2022
Read moreRead moreElevateBio BaseCamp® Unveils its LentiPeak™ Lentiviral Vector Platform
November 3, 2022
Read moreRead moreElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation
August 25, 2022
Read moreRead moreElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines
August 23, 2022
Read moreRead moreElevateBio Announces the Formation of a New Company with George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies
August 4, 2022
Read moreRead moreElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development
June 2, 2022
Read moreRead moreElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 4, 2022
Read moreRead moreElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp®
January 19, 2022
Read moreRead moreElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 6, 2022
Read moreRead moreElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform
November 15, 2021
Read moreRead moreElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics
October 27, 2021
Read moreRead moreBoston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration
June 29, 2021
Read moreRead moreElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion
June 10, 2021
Read moreRead moreElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering
April 27, 2021
Read moreRead moreElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors
March 18, 2021
Read moreRead moreElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing
March 15, 2021
Read moreRead moreElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting
December 6, 2020
Read moreRead moreElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020
Read moreRead moreElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio’s Portfolio of Innovative Cell and Gene Therapy Companies
November 16, 2020
Read moreRead moreAlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
March 23, 2020
Read moreRead moreAlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference
February 19, 2020
Read moreRead moreAlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
February 12, 2020
Read moreRead moreElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine
December 9, 2019
Read moreRead moreElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research
October 1, 2019
Read moreRead morePhase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES
September 10, 2019
Read moreRead moreMassachusetts General Hospital and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies
July 25, 2019
Read moreRead moreAlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT
June 11, 2019
Read moreRead moreElevateBio announces that allovir joins its portfolio of highly innovative cell and gene therapy companies
May 22, 2019
Read moreRead moreElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies
May 13, 2019
Read moreRead moreEuropean Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
March 26, 2020
Read moreRead more
